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Background/Aims: It has been shown that the drug-eluting beads loaded with doxorubicin (DEBDOX) are effective for the 
treatment of hepatocellular carcinoma (HCC). However, the optimal safety and efficacy still remain to be established by using 
various bead sizes, doxorubicin doses, and the degree of stasis.The aim of this study was to determine the optimal safety and 
efficacy of DEBDOX in the treatment of HCC. Methods: Analysis of a 503-patient prospective, multicenter, multinational Bead 
Registry Database from 2007 to 2010 identified 206 patients who had been treated for HCC with DEBDOX. Primary endpoints 
were to compare safety, tolerance, response rates, and overall survival based on bead size (100-300, 300-500, 500-700, and 
700-900 μm), number of vials, doxorubicin dose, and degree of stasis. Results: In total, 206 patients underwent 343 treatments. 
The use of all four bead sizes was similar based on Child-Pugh class and Okuda stage, with a significantly higher use (50%) of 
beads of size 100-300 μm in patients with portal vein thrombosis (P=0.05). Significant differences were seen for the number of 
median treatments, median doxorubicin dose, lobar infusion), and degree of complete stasis. The rate of adverse events was 
higher for larger beads than for smaller beads (28% vs. 16%; P=0.02). Conclusions: Bead size and dose may vary according to 
disease distribution. Smaller beads offer the opportunity for repeated treatments, a larger cumulative dose delivery, a lesser 
degree of complete stasis, and fewer adverse events. (Korean J Hepatol 2011;17:51-60)
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INTRODUCTION
Drug-eluting beads loaded with doxorubicin (DEBDOX) have 
recently demonstrated to have an improved safety profile and 
similar efficacy when compared to conventional transarterial 
chemoembolization (TACE) in hepatocellular carcinoma (HCC) 
patients.
1 Because of these initial improved outcomes there has 
been additional prospective reported trials demonstrating the 
effectiveness of DEBDOX with variable adverse event rates 
(Table 1).
1-5 However, optimal safety and efficacy still remains 
unanswered through the use of various bead sizes, various doxor-
ubicin doses delivered, and various degrees of stasis, following 
bead infusion with the mixed results of additional embolic agents 
utilized after initial DEBDOX use. Continued debate continues 
in regards to conventional TACE in regards to the additional use 
of embolic particles and the optimal dosing of chemotherapeutic 
agent.
6-9 Recent prospective single arm and randomized phase II 
trials continue to demonstrate this variable use with all type of 
bead sizes and bead combinations being utilized with con-
comitant variable adverse event rates and fairly comparable 
response rates (Table 1).
1-5
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Table 1. Prospective studies evaluating the use of drug-eluting beads loaded with doxorubicin (DEBDOX) for the treatment of 
hepatocellular carcinoma (HCC)
Studies Patients (n) Bead size (μ) AE (%) RR (%)
Lammer
1 93 300-500, 500-700 58 52
Varela
4 27 500-700 18 75
Malagari
3 41 100-300, 300-500 22 73
Poon
2 20 500-700 11 50
Reyes
5 20 100-300, 300-500 10 60
AE, adverse events; RR, response rates.
and efficacy of DEBDOX in the treatment of HCC by evalu-
ating bead size, dose of doxorubicin and angiographic end point.
PATIENTS AND METHODS
Patients
Written informed consent was obtained from each patient 
included in the study and the study protocol conformed to 
the ethical guidelines of the 1975 Declaration of Helsinki as 
reflected in a priori approval by each institutional IRB. This 
prospective, multi-institutional, open, non-controlled, repeat- 
treatment registry of 206 patients undergoing 343 treatments 
for HCC was evaluated from January 2007 to February 
2010. The registry satisfies the strict criteria for critical 
appraising of the quality of a registry study including a well 
described patient population, ability to generate hypotheses 
and answer questions, high quality data, with good quality 
control, independent assessment of outcomes, good clinically- 
relevant follow-up with minimal loss of patients to follow- 
ups, and comparable patient evaluation across all participating 
institutions. 
Patients aged 18 years or older with HCC unsuitable for 
resection or percutaneous ablation, without portal invasion, 
were eligible for the evaluation. A confirmed diagnosis of 
HCC according to European Association for the Study of the 
Liver (EASL), an Eastern Cooperative Oncology Group 
(ECOG) performance status of 0 or 1, and preserved liver 
function were satisfied. Patients were excluded if they had 
another primary tumor, advanced liver disease (defined as 
bilirubin levels >3 mg/dL, aspartate aminotransferase (AST) 
or alanine aminotransferase (ALT)>5×upper normal limit or
>250 U/L), advanced tumoral disease (vascular invasion, or 
contraindications for doxorubicin administration). Limited, 
focal extrahepatic disease that was felt not to be life limiting 
was allowed in this evaluation. Standard pre-therapy evaluation 
of patients with HCC included at least a three-phase 
computed tomography (CT) of the abdomen and pelvis or a 
dynamic magnetic resonance imaging (MRI) depending on 
the institution and the availability of the technology for use.
Patients were assessed for 30 days after each treatment for 
any treatment related adverse experiences, and monitored 
for two years to assess survival. All adverse events were 
recorded using the standards and terminology set forth by the 
Cancer Therapy Evaluation Program Common Terminology 
Criteria for Adverse Events, Version 3.0. Defined grade were: 
Grade 1-mild adverse events, Grade 2-moderate adverse event, 
Grade 3-severe adverse event, Grade 4-life- threatening or 
disabling adverse event, and Grade 5-death related to adverse 
event. Follow-up assessments included a tri-phase CT scan 
of the liver within at least two months of completion of 
treatment with the evaluation of the enhancement pattern of 
the target lesion and tumor response rates measured according 
to modified RECIST criteria.
Treatment with DEBDOX and outcomes
Diagnostic angiography was performed by an interven-
tional radiologist and consisted of selective celiac and supe-
rior mesenteric arteriogram to evaluate the hepatic arterial 
anatomy. For tumors near the periphery of the liver, evalua-
tion of potential extrahepatic supply to the tumors such as 
the inferior phrenic, gastroepiploic and internal mammary 
arteries was performed. Once the degree of hepatic tumor 
perfusion was evaluated, the next step was to limit any type 
of extrahepatic perfusion of the chemotherapeutic treatment. 
The most common branches that will lead to extrahepatic 
disposition of treatment are the right gastric and the gastro-
duodenal arteries, which are either controlled prior to 
infusion using coil embolization, or distal catheter placement. 
In addition, particular attention is paid to identification of 
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point. This avoids extrahepatic infusion of embolic material 
into the gallbladder and maximizes therapy control. 
The bead size used for each patient was up to the treating 
interventional radiologist, since at the time of this study no 
optimal bead size had been described. Similarly there are 
also, similar elution characteristics in all bead sizes, and thus 
the type of bead was not standardized. 
Patients originally followed a plan of either two or three 
treatment cycles based on the extent of liver involvement 
with a repeat CT scan every three months from the initial 
first treatment cycle to evaluate response as well as planned 
re-treatment. For patients with bilobar disease, a planned 
minimum of four treatments (100-150 mg each treatment, 
depending on the extent of tumor burden and the extent of 
hepatic parenchymal reserve) were loaded into two bead 
vials of similar size to those described above. The plan 
included at least two treatments per lobe every three to four 
weeks depending on toxicity, also as above. These patients 
also had a planned repeat CT scan three months from the 
first dose to evaluate tumor response. For example, if 
patients present with bilobar disease, they would receive a 
first bead treatment to the right lobe, then three weeks after a 
second bead treatment to left lobe, then three weeks later a 
third bead treatment to right lobe, and then again three 
weeks later to left lobe.
Image guided precision chemoembolization, peri-proce-
dural medications including pain medications, antibiotic 
prophylaxis and corticosteroids and proton pump inhibitors 
were all performed at the physician’s discretion.
The primary end point for this study was 12 months 
response rate and overall survival in the management of HCC.
All bead therapies were performed with the DC/LC
TM 
bead microsphere (Drug Eluting Bead [DEB]; www.bio-
compatibles.com, Biocompatibles UK, Surrey, UK). The 
saline suspension in the DC/LC
TM bead microsphere was 
removed and the beads were mixed with doxorubicin 
solution at a dose of 75 mg per 2 mL at least 4 h before the 
procedure depending on the dose that was planned to be 
delivered. The mixing of DEBDOX was performed with 
non-ionic contrast (approximately 50/50 dilution) prior to 
injection. Minimum recommended volume of loaded bead 
to contrast mixture is approximately 10.0 mL to ensure 
smooth catheter delivery. After appropriate mixing and 
removal of the un-eluted supernatant, a microcatheter is then 
placed intra-arterially. Placement is again based on the 
extent of liver disease, as described above. Any of the four 
size beads could be used for these infusions, according to 
physician evaluation. DEBDOX is injected slowly to avoid 
reflux of embolic material. Additional embolic material is 
not usually recommended after appropriate bead infusion, 
but was up to the physician’s discretion. A Lobar infusion 
was defined as catheter placement at the time of bead in-
fusion just pass the hepatic artery bifurcation, or if because 
of a late cystic arterial take off, then a posterior sectoral 
infusion followed by an anterio sector infusion such that a 
whole lobe of the liver was treated at one session. A segmen-
tal infusion was defined as at least two segments of the liver 
treated with beads and a sub-segmental infusion was defined 
as a single segment treated. The degree of stasis was defined 
as none - no change in hepatic arterial blood from before bead 
infusion, partial - defined as loss of peripheral tumor vessels, 
near - near complete loss of intra-tumoral vascularity, and 
complete - no evidence of hepatic arterial flow to tumor and 
segmental liver.
Data was censored at the last recorded patient contact if an 
endpoint was not reached. Recurrence was also evaluated 
using positron emission tomography (PET) scan. A recurrence 
was the re-occurrence of viable tumor by radiologic CT 
criteria of a vascular mass. In the event of subsequent hep-
atic therapy for recurrence of disease only the first procedure 
was used for the purposes of this study.
Statistical analysis
Chi-square, Student’s t-test, and Mann-Whitney’s U-test 
for nominal, continuous, and ordinal variables were used to 
evaluate the association of independent variables to 
complications. Proportional hazards analysis was performed 
on all variables found significant by univariate analysis. 
Relative risk (RR) with 95% confidence intervals was calcu-
lated as a measure of association. Patients with diffuse 
disease (>10 lesions) were compared to patients without 
diffuse disease. Differences of P<0.05 were considered 
significant. Statistical analysis was performed using JMP 
software (JMP, SAS Institute Inc., Cary, NC, USA).
RESULTS
A total of 206 patients were included in this review with a 
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Table 2. Clinical characteristics of HCC patients treated with DEBDOX according to bead size used
Characteristics Small (n=78) Mixed (n=40) Medium (n=74) Large (n=14) P-value
Age (years, median) (range) 68 (35-79) 65 (47-88) 66 (45-75) 68 (43-85) 0.21
Gender (M/F) 75%/25% 76%/24% 72%/28% 75%/25% 0.22
ECOG performance status 0.04
   0 80% 67% 37% 57%
   1 18% 28% 58% 17%
   2  2%  5%  5% 26%
AFP (ng/mL, median) (range) 30 (2-174,403) 30 (2.5-24,572) 26 (1-57,000) 1700 (25-252,000) 0.09
Child-Pugh status 0.15
   A 5 2 2 8 5 1 8
   B 2 5  9 2 1 5
   C  1  3  2 1
Okuda class 0.13
   1 5 9 2 9 5 4 6
   2 1 7  7 2 0 6
   3  2  4  0 2
Extent of liver lesions 0.25
   Distinct number 81% 88% 81% 83%
   Numerous 18% 12% 19% 17%
Liver involvement  0.12
   < 25% 70% 74% 60% 55%
   26-50% 23% 20% 19% 18%
   51-75%  7%  6% 21% 17%
Median number liver tumors (range) 0.04
   Total number 2 (1-25) 1 (1-9) 1 (1-25) 1 (1-3)
   Number of target 2 (1-5) 1 (1-5) 1 (1-5) 1 (1-3)
Sum of target lesions 0.17
   Size (cm, median) (range) 6 (3-19.8) 5.8 (2.4-20.5) 5.5 (2.8-20) 7.8 (3.5-21)
   Sum, Non-target lesions (cm, median) (range) 0 (0-22) 0 (0-7) 0 (0-6.4) 0 (0-0)
Lesion location 0.28
   Seg 2-3 4% 8% 16% 8%
   Seg 2-4 9% 8% 6% 0
   Seg 4-8 13% 17% 1% 17%
   Seg 5-8 25% 41% 5% 58%
   Seg 2-8 35% 20% 30% 0
   Other 14% 6% 42% 17%
Extrahepatic disease: yes 10% 11% 7% 17% 0.11
   Portal lymph nodes 2 0 2 1
   Peritoneum 2 0 0 0
   Other solid organ 2 2 2 0
   L u n g 1 2 1 1
Prior therapy 0.03
   Radiofrequency ablation 20% 19% 18% 7%
   Liver resection 13% 11%  3% 0
   Conventional TACE 21% 25% 26% 7%
   Bland embolization  3%  1%  5% 0
   Yttrium 15% 11%  2% 0
DEBDOX, drug-eluting beads loaded with doxorubicin; HCC, hepatocellular carcinoma; ECOG, Eastern Cooperative Oncology 
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Table 3. DEBDOX treatment and outcomes in HCC patients
Characteristics 
Small
(n=78)
Mixed
(n=40)
Medium
(n=74)
Large
(n=14)
P-value
Number of bead courses (range) 2 (1-8) 1 (1-4) 1 (1-6) 1 (1-3) 0.05
Total number of bead treatments
0.03
   1 6 94 57 71 8
   2 4 41 41 4 3
   3 2 0 7 7 2
   4  7 1 1 0
   >4 3 0  0  3  0
Location of treatment
0.19
   Right 59% 43% 64% 71%
   Left 39% 40% 22%  6%
   Other  2% 17% 14% 23%
Total median dose given at each treatment (mg) 
(range)
75
(30-150)
150
(50-150)
100
(25-150)
100
(50-150)
0.02
Level of branching
0.06
   Lobar 64% 39% 42% 69%
   Segmental 30% 54% 42% 31%
   Sub-segmental  5%  4% 12% 0
Flow occlusion
0.04
   Partial 32% 36% 24% 31%
   Near 31% 24% 14% 6%
   Complete 35% 40% 61% 63%
   None  2% 0 0
Other embolics used 18% 19% 10% 20% 0.19
Total cumulative dosage delivered (mg, median) 
(range)
150
(75-650)
150
(75-450)
75
(50-300)
75
(50-300)
0.03
Length of stay 23 hr
(23 hr-30 days)
1 day
(23 hr-14 days)
2 days
(23 hr-16 days)
3 days
(23 hr-21 days)
0.03
Extra-hepatic infusion 1 0 1 0
Complications 16% 14% 25% 33% 0.02
DEBDOX, drug-eluting beads loaded with doxorubicin; HCC, hepatocellular carcinoma.
combination (100-300 μ beads alone) or a medium bead 
combination (one vial 300-500 μ and one vial 500-700 μ) 
followed by a mixed bead combination (one vial of 100-300
μ and one vial of 300-500 μ) with the smallest number being 
patients treated with large beads alone (500-700 μ only). All 
four groups above were similar in age as well as male-to- 
female distribution as demonstrated in Table 2. A majority 
of small and mixed bead treated patients had a better overall 
performance status with 80% of the small bead and 67% of 
the mixed bead patients having ECOG of 0 (P=0.04). The 
alphfetoprotein levels for all four groups were similar 
median values with also similar range from as low as 2 to as 
high as 252,000 ng/mL. The percentage of patients in both 
early and late stage Child’s-Pugh status as well as early and 
late stage Okuda class was also similar across all four 
groups. The extent of disease was also similar in all four 
groups with a greater percentage of patients having less than 
25% liver involvement in the small and mixed bead treated 
patients (P=0.12). Patients treated with small beads were 
more likely to have a median number of tumors of two with 56  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011
Table 4. Adverse events related to DEBDOX treatment according to bead size used
Adverse events All patients Small (n=12) Mixed (n=6) Medium (n=19) Large (n=5)
N a u s e a 1 35152
Vomiting 10514
Anorexia 3 2 1
P a i n 93231
Liver dysfunction 10 2 6 2
Ascites 3 2 1
Fatigue 4 2 2
Ileus 2 1 1
Hyperglycemia 1 1
Infection 2 2
GI bleed 5 1 3 1
Hematologic 5 2 2 1
Hypertension 2 2
Cholecystitis 1 1
O t h e r s 7232
Total number of complications 76 27 10 32 7
DEBDOX, drug-eluting beads loaded with doxorubicin.
the remaining three groups having a median number of one 
(P=0.04). The sum of target lesions as well as the sum of all 
non-target lesions was also similar across all four groups. 
Small percentages of all four groups did have patients with 
extra-hepatic disease including portal lymph nodes, peri-
toneal metastasis, other solid organ metastasis or a lung 
metastasis. Interestingly, a majority of patient treated with 
small beads had been treated either with hepatic resection, 
radiofrequency ablation, prior conventional TACE and even 
Yttrium-90 prior to their exposure with small beads with 
DEBDOX (P=0.03).
Of the 206 patients, a total of 343 DEBDOX treatments 
were performed. Table 3 showed the DEBDOX treatments 
and outcomes of the patients. Patients treated with small 
beads were more likely to have more number of bead treat-
ments with a median of two and a range of one to eight with 
the remaining three groups having a median of one bead 
treatment and a range of one to four in a majority of all of the 
remaining three groups (P=0.05). The total dose given at 
each perspective bead treatment was similar across all three 
groups with a slightly higher dose in the medium and large 
bead treated patients. A majority of all patients were treated 
either in a lobar or segmental approach with a small percent-
age treated in a sub-segmental-type of approach. Patients 
who were treated with medium and large bead combinations 
had a statistically significant greater incidence of complete 
stasis following their bead treatment (P=0.04). There was as 
similar use across all four groups of additional embolic, that 
being either unloaded bead or other types of particles 
utilized following initial bead treatment in order to achieve a 
greater degree of stasis. The total cumulative dose given to 
the entire liver of a patient was significantly higher in the 
small and mixed bead groups with a median dose of 150 mg 
respectively and a higher range of dose delivered with as 
high as 650 mg total in the small bead patient and 450 mg 
total in the mixed bead patient (P=0.03). The length of stay 
was also statistically significantly higher in the medium and 
large bead patients with them having a median length of stay 
of two to three days in comparison to the small bead patient 
of 23 hours (P=0.03). The degree of adverse events was also 
statistically significantly higher in the large and medium 
group of patients with 33% and 25%, respectively (P=0.02) 
The types and severity of complications were fairly similar 
across all four groups (Table 4), however, there was a larger 
number of patients in the medium group who developed 
liver dysfunction and gastrointestinal bleeding that did lead 
to post-bead death in the 30-day post-treatment follow-up 
(P=0.04). The overall procedure-related mortality in the 205 
patients treated was 6.8% with a majority of all of these mor-
talities occurring in patients who were treated with either a Robert Martin, et al. Optimal technique and response of doxorubicin beads for hepatocellular carcinoma  57
Table 5. Grade of adverse events related to DEBDOX treatment according to bead size used
Grade of adverse events All patients Small (n=78) Mixed (n=40) Medium (n=19) Large (n=5)
G r a d e  1 2 0 1 01 81
G r a d e  2 2 4 1 031 1
G r a d e  3 1 9  36 55
Grade 4  3  3
Grade 5  7  1  5 1
DEBDOX, drug-eluting beads loaded with doxorubicin.
Table 6. Factors associated with the incidence of adverse events
Adverse event Yes P-value
Stasis 0.02
  Complete 26%
  N e a r 2 7 %
  Partial 11%
Level branch 0.01
  L o b a r 2 0 %
  Segmental 17%
  Sub-segmental 35%
Doxorubicin dose (mg) 0.19
  ≤ 75  7%
  76-149  5%
  150 11%
Number of bead treatment 0.21
  1 2 0 %
  2 1 2 %
  3 1 3 %
  4  0 %
medium or large bead size (Table 5).
In a review of other predictive factors for adverse event 
rates, there was a statistically significant increase in overall 
adverse event rates in patients who underwent the angio-
graphic endpoint of either a complete stasis or a near stasis 
with nearly double adverse event rates in patients who had 
partial stasis (Table 6). Similarly there was also a statisti-
cally significant increase in adverse advent rates in patients 
who were treated in a sub-segmental DEBDOX infusion in 
relation to patients who received only lobar or segmental 
infusion, however, there were no significant differences in 
adverse event rates related to the doxorubicin dose delivered 
with similar adverse event rates in patients who received less 
than equal to 75 mg (7% adverse event rate), 76-150 mg (5% 
adverse event rate) or 150 mg (11% adverse event rates). 
Similarly, regardless if a patient was undergoing their first 
bead treatment or their, fourth bead treatment, there was also 
none statistically significant difference in overall adverse 
event rates, regardless of the number of bead treatments that 
the patient was undergoing.
In a review of 6 month and 12 months response rates there 
were similar response rates in all four groups (Table 7), with 
small bead demonstrating 6 months of 73% and 12 month of 
61%, Mixed was 88% and 50%, Medium was 60% and 57%, 
and Large was 57% and 46% respectively. After a median 
follow up of 12 months, similar overall survival was seen in 
all groups with small bead median of 16 months, mixed 13 
months, medium 14 months, and large 11 months (P=0.2). 
DISCUSSION
DEBDOX has been proven in multiple studies to demon-
strate enhanced anti-tumor effects with similar or increased 
survival and decrease in overall side effects related to other 
hepatic arterial therapies. Response rates in all series have 
ranged from as low as 50% at 6 months, to as high as 70% at 
6 months based on various reports. Varela et al
10 reported 
response rates of 60-70% and similarly reported only minor 
overall adverse event rate of 18%, even with the use of a 
single vial of 500-700 μ beads but did report 2 patients with 
liver abscess (7.4%) and 1 death (3.7%). The degree of stasis 
and degree of doxorubicin dose delivered for this specific 
patient is not revealed in this manuscript and thus the true 
source for this adverse event rate is not able to be delineated. 
A similar smaller Phase II study by Poon et al
11 also used 
the same bead size and did demonstrate an a small adverse 
event rate of 11% and did not report any liver abscess or 
death, thus demonstrating the potential safety of beads up to 
500-700 μ in size.
However, in contrast, the recent randomized phase II 
Precision V Trial, which utilized a combination bead size of 
300-500 μ followed by 500-700 μ beads showed a dramatic 58  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011
Table 7. Response rates for all of the evaluated patients
Response
6 months 12 months
Small
(n=78)
Mixed
(n=40)
Medium
(n=74)
Large
(n=14)
Small
(n=73)
Mixed
(n=38)
Medium
(n=69)
Large
(n=13)
Complete response 17 11 20 4 12  7 10 3
Partial response 40 15 25 4 33 12 30 3
S t a b l e  d i s e a s e  6 81 7 3  5 51 0 2
Progression of disease 10  4  7 2  8  3 10 3
Not Reached time point  0  0  0 0 10  8  0 2
Mortality by disease  4  2  0 0  5  3  4 0
Mortality by complication  1  0  5 1  0  0  5 0
increase of overall adverse event rate of 58% with this 
combination bead size.
12 However, other predictive factors 
of adverse events being type of segmental infusion as well as 
degree of stasis were not evaluated in this randomized phase 
II trial, thus delineating if this is related to the bead size 
alone or in combination, the bead size, the angiographic 
technique and the end point is not able to be truly delineated 
in this reported trial.
In an evaluation of a smaller bead size combination by 
Malagari et al
13 who utilized a 100-300 μ and then 300-500 μ
bead size, adverse event rates were dramatically less with an 
overall of 22%. The explanation for the use of 100-300 μ and 
300-500 μ are specifically explained in this trial and are 
related to lesion size (<6 cm or ≥6 cm or the presence or absence 
of arteriovenous shunts). Given that this was an overall 
survival comparison of DEBDOX to bland embolization, 
the evaluation of the bead size, degree of stasis, and degree 
of doxorubicin and drug delivered, was not a primary end 
point and thus was not reported in this manuscript. They did, 
however, report a liver abscess rate of 4.8% and a liver 
failure rate, also of 4.8%, similar to the previously reported 
trials. 
All of the previous studies present an overall adverse 
event rates, but do not answer what is the optimal bead size, 
optimal doxorubicin dose and angiographic techniques. Herein 
the results of this prospective multi institutional registry 
does demonstrate a statistically significant increase in overall 
adverse event rates as well as severe adverse event rates, 
being death in patients who are receiving a larger bead 
combination of either 300-500 μ, 500-700 μ, or 500-700 μ 
alone. The predominant predictors of this adverse event rate 
do appear to be generated because of a higher incidence of 
complete stasis as well as a preponderance for a segmental 
or sub-segmental bead infusion. Lastly, this group of larger 
bead size was also more commonly being treated with additional 
embolic agents following DEBDOX treatment, thus potentiating 
the overall anoxic event and leading to a greater incidence of 
complications relative to hepatic ischemia. In contrast, even 
though there was a greater incidence of either complete or 
near stasis we do not see an enhanced response rate at either 
6 or 12 months in patients treated with a larger bead size. 
Thus, calling into the question as to whether efficacy is 
improved by either relative hypoxia and repeated at doxorubicin 
drug delivery versus complete anoxia at the time of initial 
chemoembolization therapy.
14-16 This data does not allow us 
to answer that question but does demonstrate significant 
better tolerance and improvement in overall survival in 
patients who were able to undergo repeated DEBDOX based 
treatment. This improvement in overall survival appears to 
be related to a greater tolerance of the patient and the 
subsequent tolerance of the diseased liver to then undergo 
repeated bead treatments because of a reduction in overall 
adverse event rates. Given the complexity of treating HCC is 
a bi-modal type of disease, that being treatment of both the 
cancer as well as the underlying hepatic parenchyma, it is 
reasonable to assume that a greater tolerance of treatment 
that is able to be able to retreat at set intervals would portend 
to an improvement in overall outcomes because of a reduction 
in toxicity. This logic is well established in the medical 
oncology literature in the fact that patients who have significant 
toxicity and are reliant on significant dose reduction of systemic 
chemotherapy or dose delays of systemic chemotherapy do 
not achieve the similar benefits of patients who are able to be 
treated at full dose and on schedule. It is thus acceptable to 
make that correlation with the use of DEBDOX based treatment 
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at appropriate intervals with reduced toxicity will thus have 
an improved overall outcome versus patients who are only 
able to be undertreated with significant toxicity. 
These results are confirmed by previous reports evaluating 
conventional TACE in which Leung et al
17 found that 
gallbladder embolization and dose administered were 
associated with an increased risk of post embolic syndrome 
and an extended hospitalization, with odds ratios of 2.8 and 
3.0, and 3.0 and 4.6, respectively. Previous embolization 
was associated with a decreased risk of both post embolic 
syndrome and extended hospitalization, with odds ratios of 
0.5 and 0.4, respectively. They concluded that clinically re-
levant predictors of the severity of post embolic syndrome 
and length of post procedural hospitalization may exist 
through avoiding embolization of the gallbladder, and that 
re-embolization of previously treated vessels is associated 
with decreased toxicity and may assist in selecting patients 
for treatment on an outpatient basis. However, in a review of 
Patel et al, no definitive predictors were found.
18
The limitations of this study are also, potentially, the bene-
fits in that this evaluation was not formed on an established 
prospective protocol. However, the data present is real clinical 
practice in patients who are initiating DEBDOX based 
treatment in their interventional oncology practices. We 
believe that this, obviously, demonstrates a more clinically 
relevant and more clinically practical use of this device and 
believe that this type of prospective evaluation and review 
will allow additional new users and established DEBDOX 
users at the present to consider technical changes. However, 
we acknowledge that since this is not a randomized trial of 
all four bead sizes there is inherent bias that can be conveyed. 
We believe the similar groups based on disease presentation 
overcome some of this bias, but a randomized trial would be 
the optimal study to confirm these observational results.
Thus, in conclusion, based on this review of optimal bead 
size, optimal doxorubicin dosing, as well as angiographic 
technique, the smallest bead size being 100-300 μ offers the 
ability of repeat retreatment at appropriate intervals. This 
then allows for a larger cumulative dose delivery, less degree 
of complete stasis, fewer adverse event rates, and reduction 
in the severity of adverse event rates.
Conflict of interest
Dr. Martin is a consultant for Biocompatibles.
REFERENCES
1. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. 
Prospective randomized study of doxorubicin-eluting-bead embolization 
in the treatment of hepatocellular carcinoma: results of the PRECISION 
V study. Cardiovasc Intervent Radiol 2010;33:41-52.
2. Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, et al. A phase I/II 
trial of chemoembolization for hepatocellular carcinoma using a novel 
intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007;5: 
1100-1108.
3. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos 
T, et al. Prospective randomized comparison of chemoembolization 
with doxorubicin-eluting beads and bland embolization with BeadBlock 
for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33: 
541-551.
4. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. 
Chemoembolization of hepatocellular carcinoma with drug eluting 
beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 
46:474-481.
5. Reyes DK, Vossen JA, Kamel IR, Azad NS, Wahlin TA, Torbenson MS, 
et al. Single-center phase II trial of transarterial chemoembolization 
with drug-eluting beads for patients with unresectable hepatocellular 
carcinoma: initial experience in the United States. Cancer J 2009;15: 
526-532.
6. Maluccio M, Covey AM, Gandhi R, Gonen M, Getrajdman GI, Brody 
LA, et al. Comparison of survival rates after bland arterial embolization 
and ablation versus surgical resection for treating solitary hepatocellular 
carcinoma up to 7 cm. J Vasc Interv Radiol 2005;16:955-961.
7. Maluccio MA, Covey AM, Porat LB, Schubert J, Brody LA, Sofocleous 
CT, et al. Transcatheter arterial embolization with only particles for the 
treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 
2008;19:862-869.
8. Brown KT, Nevins AB, Getrajdman GI, Brody LA, Kurtz RC, Fong Y, 
et al. Particle embolization for hepatocellular carcinoma. J Vasc Interv 
Radiol 1998;9:822-828.
9. Kawai S, Okamura J, Ogawa M, Ohashi Y , T ani M, Inoue J, et al. 
Prospective and randomized clinical trial for the treatment of hepa-
tocellular carcinoma-a comparison of lipiodol-transcatheter arterial 
embolization with and without adriamycin (first cooperative study). 
The Cooperative Study Group for Liver Cancer Treatment of Japan. 
Cancer Chemother Pharmacol 1992;31(Suppl):S1-S6.
10. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. 
Chemoembolization of hepatocellular carcinoma with drug eluting 
beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46: 
474-481.
11. Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, et al. A phase I/II 
trial of chemoembolization for hepatocellular carcinoma using a novel 
intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007;5: 
1100-1108.
12. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. 
Prospective randomized study of doxorubicin-eluting-bead embolization 
in the treatment of hepatocellular carcinoma: results of the PRECISION 
V study. Cardiovasc Intervent Radiol 2010;33:41-52.
13. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos 
T, et al. Prospective randomized comparison of chemoembolization 
with doxorubicin-eluting beads and bland embolization with BeadBlock 
for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33: 
541-551.
14. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. 
Transcatheter arterial chemoembolization (TACE) in hepatocellular 
carcinoma (HCC): the role of angiogenesis and invasiveness. Am J 
Gastroenterol 2008;103:914-921. 60  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011
15. Mamori S, Asakura T, Ohkawa K, Tajiri H. Survivin expression in early 
hepatocellular carcinoma and post-treatment with anti-cancer drug 
under hypoxic culture condition. World J Gastroenterol 2007;13: 
5306-5311.
16. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of 
mitosis and apoptosis and novel target for cancer therapeutics. Clin 
Cancer Res 2008;14:5000-5005.
17. Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of 
postembolization syndrome after hepatic chemoembolization. J Vasc 
Interv Radiol 2001;12:321-326. 
18. Patel NH, Hahn D, Rapp S, Bergan K, Coldwell DM. Hepatic artery 
embolization: factors predisposing to postembolization pain and 
nausea. J Vasc Interv Radiol 2000;11:453-460.